These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33359624)

  • 1. Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance.
    Khot VM; Salunkhe AB; Pricl S; Bauer J; Thorat ND; Townley H
    Drug Discov Today; 2021 Mar; 26(3):724-739. PubMed ID: 33359624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silica nano supra-assembly for the targeted delivery of therapeutic cargo to overcome chemoresistance in cancer.
    Thorat ND; Bauer J; Tofail SAM; Gascón Pérez V; Bohara RA; Yadav HM
    Colloids Surf B Biointerfaces; 2020 Jan; 185():110571. PubMed ID: 31683204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs.
    Huang W; Chen L; Kang L; Jin M; Sun P; Xin X; Gao Z; Bae YH
    Adv Drug Deliv Rev; 2017 Jun; 115():82-97. PubMed ID: 28624478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can nanomedicines kill cancer stem cells?
    Zhao Y; Alakhova DY; Kabanov AV
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1763-83. PubMed ID: 24120657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in nanomedicine for enhanced cancer chemotherapy.
    Wei G; Wang Y; Yang G; Wang Y; Ju R
    Theranostics; 2021; 11(13):6370-6392. PubMed ID: 33995663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
    Chen Z; Zheng Y; Shi Y; Cui Z
    Int J Nanomedicine; 2018; 13():319-336. PubMed ID: 29391792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptamer-guided nanomedicines for anticancer drug delivery.
    Alshaer W; Hillaireau H; Fattal E
    Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance.
    Sa P; Sahoo SK; Dilnawaz F
    Curr Med Chem; 2023; 30(29):3335-3355. PubMed ID: 36154585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmable nanomedicine: synergistic and sequential drug delivery systems.
    Pacardo DB; Ligler FS; Gu Z
    Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
    He Q; Shi J
    Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor targeting via EPR: Strategies to enhance patient responses.
    Golombek SK; May JN; Theek B; Appold L; Drude N; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2018 May; 130():17-38. PubMed ID: 30009886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models.
    Petrikaite V; D'Avanzo N; Celia C; Fresta M
    Drug Resist Updat; 2023 May; 68():100956. PubMed ID: 36958083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
    Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
    Mao C; Li F; Zhao Y; Debinski W; Ming X
    Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current prospects and challenges of nanomedicine delivery in prostate cancer therapy.
    Gupta S; Gupta PK; Dharanivasan G; Verma RS
    Nanomedicine (Lond); 2017 Dec; 12(23):2675-2692. PubMed ID: 29098929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in targeted nanomedicine as promising antitumor therapeutics.
    Hejmady S; Pradhan R; Alexander A; Agrawal M; Singhvi G; Gorain B; Tiwari S; Kesharwani P; Dubey SK
    Drug Discov Today; 2020 Dec; 25(12):2227-2244. PubMed ID: 33011342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.